The final, formatted version of the article will be published soon.
REVIEW article
Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 15 - 2025 |
doi: 10.3389/fonc.2025.1530541
This article is part of the Research Topic Renewed Insight into Cancer Mechanism and Therapy View all 14 articles
Adoptive Cell Therapy Against Tumor Immune Evasion: Mechanisms, Innovations, and Future Directions
Provisionally accepted- Jiujiang First People's Hospital, Jiujiang, China
Abstract：Tumors employ a range of strategies to evade detection and eradication by the host's immune system. These include downregulating antigen expression, altering antigen presentation processes, and inhibiting immune checkpoint pathways. etc.Adoptive Cell Therapy (ACT) represents a strategy that boosts anti-tumor immunity. This is achieved by amplifying or genetically engineering immune cells, which are either sourced from the patient or a donor, in a laboratory setting.Subsequently, these cells are reintroduced into the patient to bolster their immune response against cancer.ACT has successfully restored anti-tumor immune responses by amplifying the activity of T cells from patients or donors.This review focuses on the mechanisms underlying tumor escape, including alterations in tumor cell antigens, the immunosuppressive tumor microenvironment (TME), and modulation of immune checkpoint pathways. It further explores how ACT can address these factors to enhance therapeutic efficacy. Additionally, the review discusses the application of gene-editing technologies (such as CRISPR) in ACT, highlighting their potential to strengthen the anti-tumor capabilities of T cells. Looking forward, the personalized design of ACT, combined with immune checkpoint inhibitors and targeted therapies, is expected to significantly improve treatment outcomes, positioning this approach as a key strategy in the field of cancer immunotherapy.
Keywords: adoptive cell therapy, Tumor Microenvironment, Immune Evasion, Cancer mechansims, personalized treatment
Received: 19 Nov 2024; Accepted: 06 Feb 2025.
Copyright: © 2025 Ruan and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Lu Wang, Jiujiang First People's Hospital, Jiujiang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.